Vectibix Dosage/Direction for Use

Vectibix treatment should be supervised by a physician experienced in the use of anti-cancer therapy.
Evidence of wild-type RAS (KRAS and NRAS) status is required before initiating treatment with Vectibix. Mutational status should be determined by an experienced laboratory using validated test methods for detection of KRAS (exons 2, 3, and 4) and NRAS (exons 2, 3, and 4) mutations.
Posology: The recommended dose of Vectibix is 6 mg/kg of bodyweight given once every two weeks.
Prior to infusion, Vectibix should be diluted in 0.9% sodium chloride to a final concentration not to exceed 10 mg/mL (for preparation instructions see Instructions for Use/Handling under Cautions for Usage).
Modification of the dose of Vectibix may be necessary in cases of severe (≥ grade 3) dermatological reactions (see Precautions).
Special populations: The safety and efficacy of Vectibix have not been studied in patients with renal or hepatic impairment.
There is no clinical data to support dose adjustments in the elderly.
Paediatric population: There is no relevant use of Vectibix in the paediatric population in the indication treatment of colorectal cancer.
Method of administration: Vectibix must be administered as an intravenous infusion via an infusion pump, using a low protein binding 0.2 or 0.22 micrometre in-line filter, through a peripheral line or indwelling catheter. The recommended infusion time is approximately 60 minutes. If the first infusion is tolerated, then subsequent infusions may be administered over 30 to 60 minutes. Doses higher than 1,000 mg should be infused over approximately 90 minutes (for handling instructions, see Instructions for Use/Handling under Cautions for Usage).
The infusion line should be flushed with sodium chloride solution before and after Vectibix administration to avoid mixing with other medicinal products or intravenous solutions.
A reduction in the rate of infusion of Vectibix may be necessary in cases of infusion-related reactions (see Precautions).
Vectibix must not be administered as an intravenous push or bolus.
For instructions on dilution of the medicinal product before administration, see Instructions for Use/Handling under Cautions for Usage.